Results 141 to 150 of about 26,059 (187)

Medicare Part D Savings Under the Manufacturer Discount Program vs Coverage Gap Discounts.

JAMA Netw Open
Rome BN, Garrett KR, Maini L.
europepmc   +1 more source

Correction: Evaluation of the responsiveness of the Iranian health system to the needs of the elderly during the COVID-19 pandemic: a community-based study. [PDF]

BMC Health Serv Res
Niazie S, Heydari H, Hayati H, Dehghani A.   +3 more
europepmc   +1 more source

Note on targeted learning with an undersmoothed Lasso propensity score model for large-scale covariate adjustment in health care database studies. [PDF]

Am J Epidemiol
Wyss R, van der Laan M, Gruber S, Shi X, Lee H, Dutcher SK, Nelson JC, Toh S, Russo M, Wang SV, Desai RJ, Lin KJ.   +11 more
europepmc   +1 more source

Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China. [PDF]

Ther Adv Med Oncol
Ding B, Yao H, Tao T, Sun Y, Zhu Y, Zhu H, Wang J, Jing Z, Gao L, Lin Y, Li X.   +10 more
europepmc   +1 more source

Revenue Differences Between Top-Selling Small-Molecule Drugs and Biologics in Medicare.

JAMA Health Forum
Vogel M, Feldman WB, Cowan Z, Rome BN, Chandra A, Kesselheim AS, Wouters OJ.   +6 more
europepmc   +1 more source

Translation and Cultural Adaptation of the Measure Yourself Concerns and Wellbeing (MYCaW) Questionnaire Into German: Protocol for the iSWOP Study.

JMIR Res Protoc
Thronicke A, Schille L, Adie K, Junghanss C, Oei SL, Johnson S, Roos J, Schad F.   +7 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Pay-Per-Click Direct-to-Consumer Advertising.

JAMA Netw Open
Eisenkraft Klein D, Zenone M, Kesselheim AS.   +2 more
europepmc   +1 more source

Regulatory and Clinical Outcomes of Nononcology Accelerated Approvals.

JAMA
Liu ITT, Reynolds G, Kesselheim AS, Cliff ERS.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interventional Pharmacoeconomics

The Cancer Journal, 2020
Abstract The increasing cost of health care is a major challenge around the world, but particularly in the United States. One reason for increased costs is the rapidly rising cost of oncology drugs. Potential solutions to this problem involve broad changes to health policy. However, an alternative solution is the development of lower-cost off-
Daniel A, Goldstein, Garth W, Strohbehn, Anthony V, Serritella, David A, Hyman, Allen S, Lichter, Mark J, Ratain   +5 more
openaire   +3 more sources

Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.

Clinical pharmacology and therapy, 2020
Cancer care's sustainability is challenged by drug expenditures. In the absence of systemic change, innovation is needed to curtail drug costs. Interventional pharmacoeconomics (IVPE) utilizes clinical research to identify safe, efficacious, cost ...
Anthony V. Serritella, G. Strohbehn, D. Goldstein, A. Lichter, M. Ratain   +4 more
semanticscholar   +1 more source